MDS Clinical Trial
Official title:
Chidamide Plus Post-transplantation Cyclophosphamide and Cyclosporine to Prevent Graft-versus-host Disease After Myeloablative Conditioning, Matched Peripheral-blood Stem-cell Transplantation
Verified date | July 2018 |
Source | Sichuan University |
Contact | Jie Ji, MD |
Phone | 86-28-85422373 |
jieji[@]scu.edu.cn | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is to explore the efficacy and safety of introduction of chidamide in PTCy based GVHD prophylaxis in patients undergoing allogeneic PBSCT.
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | March 30, 2021 |
Est. primary completion date | December 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Age = 16 years or older, and = 65 years at time of enrollment 2. Signed informed consent 3. Hematologic disorder requiring allogeneic hematopoietic cell transplantation 4. Left ventricular ejection fraction (LVEF) = 45% by multiple uptake gated acquisition (MUGA) scan or echocardiogram 5. Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and diffusing lung capacity oxygenation (DLCO) adjusted = 50% of predicted values on pulmonary function tests 6. Transaminases (AST, ALT) < 3 times upper limit of normal (ULN) values 7. Creatinine clearance calculated = 50 mL/min 8. Karnofsky Performance Status Score = 60%. 9. Human leukocyte antigen (HLA) matched 8/ (A, B, C, DRB1) related or unrelated donor Exclusion Criteria: 1. Active infection not controlled with appropriate antimicrobial therapy HIV, hepatitis B (HBcAb positive but HBsAg negative with undetectable viral load are eligible), or hepatitis C infection 2. Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) =4 3. Anti-thymocyte globulin (ATG) as part of the conditioning regimen 4. Pregnancy 5. Histone deacetylase (HDAC), DAC, HSP90 inhibitors or valproic acid for the treatment of cancer within 30 days 6. Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first chidamide treatment 7. Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: Any history of ventricular fibrillation or torsade de pointes; Bradycardia defined as heart rate (HR)< 45 bpm (Patients with pacemakers are eligible if HR = 45 bpm); Screening electrocardiogram (ECG) with a QTcF > 480 msec; Right bundle branch block + left anterior hemiblock (bifascicular block); Patients with myocardial infarction or unstable angina = 12 months prior to starting study drug; Other clinically significant heart disease (e.g., New York Heart Association (NYHA) class III or IV , uncontrolled hypertension) as per discretion of principal investigator and/or treating physician; Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug with the exception of drugs listed on Appendix B of study documents that are required for hematopoietic cell transplantation (HCT) patients. |
Country | Name | City | State |
---|---|---|---|
China | West China Hospital of Sichuan University | Chengdu | Sichuan |
China | West China Hospital of Sichuan University | Chengdu | Sichuan |
Lead Sponsor | Collaborator |
---|---|
Sichuan University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | aGVHD | accumulated incidence of aGVHD | 100 day after infusion of PBSCs | |
Secondary | GRFS | GVHD free, relapse free survival | 3 years after recruitment | |
Secondary | DFS | Disease free survival | 3 years after recruitment | |
Secondary | OS | Overall survival | 3 years after recruitment | |
Secondary | cGVHD | accumulated incidence of cGVHD | 2 yeas after infusion of PBSCs |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04623944 -
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
|
Phase 1 | |
Recruiting |
NCT03680677 -
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
|
||
Recruiting |
NCT05009537 -
Optical Genome Mapping in Hematological Malignancies
|
||
Not yet recruiting |
NCT04110925 -
Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CVD) Disease in Patients With Myelodysplasia
|
N/A | |
Terminated |
NCT04638309 -
APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
|
Phase 1 | |
Completed |
NCT03466320 -
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03138395 -
iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML
|
N/A | |
Completed |
NCT04443751 -
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 1 | |
Completed |
NCT02103478 -
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
|
Phase 1/Phase 2 | |
Completed |
NCT00863148 -
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
Completed |
NCT00761449 -
Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5
|
Phase 2 | |
Completed |
NCT00692926 -
Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells
|
Phase 1 | |
Terminated |
NCT00176930 -
Stem Cell Transplant for Hematological Malignancy
|
N/A | |
Completed |
NCT02214407 -
Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML
|
Phase 3 | |
Recruiting |
NCT05582902 -
Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients
|
||
Not yet recruiting |
NCT05024877 -
Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia
|
Phase 2/Phase 3 | |
Completed |
NCT00321711 -
Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents
|
Phase 2 | |
Recruiting |
NCT06156579 -
Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML
|
Phase 2 | |
Recruiting |
NCT05226455 -
Venetoclax in Patients With MDS or AML in Relapse After AHSCT
|
Phase 1/Phase 2 | |
Completed |
NCT01690507 -
Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML)
|
Phase 1/Phase 2 |